CrossrefInfokarte
Sustained biochemical control in patients with acromegaly treated with lanreotide depot 120 mg administered every 4 weeks, or an extended dosing interval of 6 or 8 weeks: a pharmacokinetic approach
Research and Reports in Endocrine Disorders · 2012
DOI: 10.2147/rred.s38149 ↗Abstract
Kein Abstract verfügbar.
EUVIMED